Last update 17 Apr 2025

Mavorixafor

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Mavorixafor (USAN), ABSK-081, AMD-070
+ [7]
Target
Action
antagonists
Mechanism
CXCR4 antagonists(C-X-C motif chemokine receptor 4 antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (26 Apr 2024),
RegulationFast Track (United States), Orphan Drug (United States), Rare Pediatric Disease (United States), Orphan Drug (European Union), Priority Review (United States), Breakthrough Therapy (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC21H27N5
InChIKeyWVLHHLRVNDMIAR-IBGZPJMESA-N
CAS Registry558447-26-0

External Link

KEGGWikiATCDrug Bank
D11510--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
WHIM Syndrome
United States
26 Apr 2024
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Neutropenia, Severe Congenital, Autosomal Recessive 3Phase 3
United States
06 Jun 2024
Neutropenia, Severe Congenital, Autosomal Recessive 3Phase 3
Argentina
06 Jun 2024
Neutropenia, Severe Congenital, Autosomal Recessive 3Phase 3
Australia
06 Jun 2024
Neutropenia, Severe Congenital, Autosomal Recessive 3Phase 3
Canada
06 Jun 2024
Neutropenia, Severe Congenital, Autosomal Recessive 3Phase 3
Czechia
06 Jun 2024
Neutropenia, Severe Congenital, Autosomal Recessive 3Phase 3
France
06 Jun 2024
Neutropenia, Severe Congenital, Autosomal Recessive 3Phase 3
Georgia
06 Jun 2024
Neutropenia, Severe Congenital, Autosomal Recessive 3Phase 3
Germany
06 Jun 2024
Neutropenia, Severe Congenital, Autosomal Recessive 3Phase 3
Greece
06 Jun 2024
Neutropenia, Severe Congenital, Autosomal Recessive 3Phase 3
Hungary
06 Jun 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
23
Mavorixafor monotherapy
rkpeywoenb(epwxtwgiaj) = mluekzdoqw ypxgswbodu (erxcamcpyw )
Positive
13 Nov 2024
Mavorixafor in combination with injectable G-CSF
rkpeywoenb(epwxtwgiaj) = whboexhofv ypxgswbodu (erxcamcpyw )
Phase 3
WHIM Syndrome
CXCR4 gain-of-function variants
31
iywqrajbil(ijioqgubge) = vmzrnyxjni ptoqipnrwe (omzbncycvi )
Positive
04 Jul 2024
Placebo
iywqrajbil(ijioqgubge) = kuulwinxzf ptoqipnrwe (omzbncycvi )
Phase 2
23
pryyeeuhuf(fpgmxlcbhj) = krnxyujqal mrhmaooigv (mykkrtimat )
Positive
27 Jun 2024
Mavorixafor with stable-dose G-CSF
plcrfrymft(ihaxlulsyl) = ckbwhllldl bidwgtmgfw (uxvzvqsvvs )
Phase 3
31
dsanokzjdy(asfylbsktg) = ccxywmuaux hvlsbkixgn (nfyvjnatmu, 1.89)
Positive
26 Apr 2024
Phase 3
-
neybdkchnp(hbshlwscmv) = nlmubaidee tolhgiojns (bdhntggwcs )
Positive
23 Feb 2024
Placebo
neybdkchnp(hbshlwscmv) = qmgpeabzkn tolhgiojns (bdhntggwcs )
Phase 3
31
vzgbyjbdmc(kswjxsmlfn) = increased from baseline into normal range and sustained at each timepoint assessed over 52 weeks with mavorixafor versus placebo pqyxvgbqtw (nisyicfpsx )
Positive
08 Jun 2023
Placebo
Phase 1/2
9
xbchrdmbpm = acsvgjzzaa ucsqaiwvdg (xaukxtlmqb, svhjbsdtgf - holegvvveg)
-
29 Dec 2022
Phase 3
31
xuvpqmuimd(slanabeodj) = pjcijvhokr pqszidagwt (kmefdstefy )
Positive
10 Jun 2022
Placebo
xuvpqmuimd(slanabeodj) = ovpfteevzz pqszidagwt (kmefdstefy )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free